Pain relief supplement no Tylenol, NAD says
This article was originally published in The Tan Sheet
U.S. firm EuroPharma markets supplement Curamin as a fast-acting analgesic pain reliever like Tylenol and Advil, but the product can "at best" provide some pain relief over time and is not "fast acting" as ads suggest, the National Advertising Division says Oct. 19. The Council of Better Business Bureaus unit brought the challenge itself, under its work supported by a Council for Responsible Nutrition grant, and recommends EuroPharma modify or discontinue certain claims for Curamin, including that it "relieves pain fast and effective" and that users can "experience better relief than ever before." EuroPharma based the claims on tests comparing the product's curcumin and boswellia ingredients to those found in OTC analgesics. However, NAD determined "there was no evidence that Curamin is either 'fast-acting' or offers 'quick results starting with day one.'" NAD recommends the firm discontinue all "fast relief" claims and others suggesting the product provides "unprecedented levels" of relief. The Green Bay, Wis., firm agreed to modify ads to more accurately reflect its studies
You may also be interested in...
Ultra Botanica’s supporting research relied on human studies with one to three participants and mice studies without direct comparisons to competing products.
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.